116 related articles for article (PubMed ID: 7627696)
1. Probucol treatment decreases serum concentrations of diet-derived antioxidants.
Elinder LS; Hådell K; Johansson J; Mølgaard J; Holme I; Olsson AG; Walldius G
Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1057-63. PubMed ID: 7627696
[TBL] [Abstract][Full Text] [Related]
2. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
Johansson J; Olsson AG; Bergstrand L; Elinder LS; Nilsson S; Erikson U; Mölgaard J; Holme I; Walldius G
Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1049-56. PubMed ID: 7627695
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of probucol and cholestyramine to lower serum cholesterol.
Boyden TW; Totman L
J Clin Pharmacol; 1981 Jan; 21(1):48-51. PubMed ID: 7217343
[TBL] [Abstract][Full Text] [Related]
4. The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST).
Walldius G; Regnström J; Nilsson J; Johansson J; Schäfer-Elinder L; Moelgaard J; Hådell K; Olsson AG; Carlson LA
Am J Cardiol; 1993 Feb; 71(6):15B-19B. PubMed ID: 8434556
[TBL] [Abstract][Full Text] [Related]
5. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
[TBL] [Abstract][Full Text] [Related]
6. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits.
Hong SC; Zhao SP; Wu ZH
J Cardiovasc Pharmacol; 2006 Jan; 47(1):77-81. PubMed ID: 16424789
[TBL] [Abstract][Full Text] [Related]
7. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
Walldius G; Erikson U; Olsson AG; Bergstrand L; Hådell K; Johansson J; Kaijser L; Lassvik C; Mölgaard J; Nilsson S
Am J Cardiol; 1994 Nov; 74(9):875-83. PubMed ID: 7977117
[TBL] [Abstract][Full Text] [Related]
8. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
Anderson TJ; Meredith IT; Yeung AC; Frei B; Selwyn AP; Ganz P
N Engl J Med; 1995 Feb; 332(8):488-93. PubMed ID: 7830729
[TBL] [Abstract][Full Text] [Related]
9. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
Lee HS; Jeong JY; Kim BC; Kim YS; Zhang YZ; Chung HK
Kidney Int; 1997 Apr; 51(4):1151-9. PubMed ID: 9083281
[TBL] [Abstract][Full Text] [Related]
10. Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
Walldius G; Carlson LA; Erikson U; Olsson AG; Johansson J; Mölgaard J; Nilsson S; Stenport G; Kaijser L; Lassvik C
Am J Cardiol; 1988 Jul; 62(3):37B-43B. PubMed ID: 3293415
[TBL] [Abstract][Full Text] [Related]
11. Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentrations.
Schwenke DC; Behr SR
Circ Res; 1998 Aug; 83(4):366-77. PubMed ID: 9721693
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of probucol and benzafibrate on lipoprotein metabolism and liver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits.
Ou J; Saku K; Jimi S; Liao YL; Ohta T; Zhang B; Arakawa K
Jpn Circ J; 1999 Jun; 63(6):471-7. PubMed ID: 10406588
[TBL] [Abstract][Full Text] [Related]
13. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro.
Regnström J; Walldius G; Carlson LA; Nilsson J
Atherosclerosis; 1990 May; 82(1-2):43-51. PubMed ID: 2360919
[TBL] [Abstract][Full Text] [Related]
14. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
El-Swefy S; Schaefer EJ; Seman LJ; van Dongen D; Sevanian A; Smith DE; Ordovas JM; El-Sweidy M; Meydani M
Atherosclerosis; 2000 Apr; 149(2):277-86. PubMed ID: 10729377
[TBL] [Abstract][Full Text] [Related]
15. Effect of the anti-oxidant probucol on soluble thrombomodulin (sTM) in hypercholesterolemic rabbits.
Hong SC; Zhao SP; Liu Q; Wu ZH
Int J Cardiol; 2008 Jan; 123(2):180-2. PubMed ID: 17292497
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia.
Masana L; Bargalló MT; Plana N; LaVille A; Casals I; Solà R
Am J Cardiol; 1991 Oct; 68(9):863-7. PubMed ID: 1927944
[TBL] [Abstract][Full Text] [Related]
17. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.
Jula A; Marniemi J; Huupponen R; Virtanen A; Rastas M; Rönnemaa T
JAMA; 2002 Feb; 287(5):598-605. PubMed ID: 11829698
[TBL] [Abstract][Full Text] [Related]
18. Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.
LeLorier J; DuBreuil-Quidoz S; Lussier-Cacan S; Huang YS; Davignon J
Arch Intern Med; 1977 Oct; 137(10):1429-34. PubMed ID: 335998
[TBL] [Abstract][Full Text] [Related]
19. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
Regnström J; Walldius G; Nilsson S; Elinder LS; Johansson J; Mölgaard J; Holme I; Olsson AG; Nilsson J
Atherosclerosis; 1996 Sep; 125(2):217-29. PubMed ID: 8842353
[TBL] [Abstract][Full Text] [Related]
20. The long-term effects of probucol on serum lipid levels.
McCaughan D
Arch Intern Med; 1981 Oct; 141(11):1428-32. PubMed ID: 7025778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
